
Six Biotech Firms Race to Cure Common Liver Disease
After the first treatment for a severe liver disease was approved in 2024, six biotechnology companies are now racing to develop the next generation of therapies. Their work could transform treatment for millions suffering from a condition affecting the liver, obesity, and diabetes.
